Injection Device

A thermal bridge in the injection device addresses the discomfort issue by rapidly heating medication from refrigerated storage to body temperature, enhancing user comfort during administration.

JP7583828B2Active Publication Date: 2024-11-14SANOFI SA(FR)
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
JP2022559895
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2020-04-03
Filing Date
2021-03-31
Publication Date
2024-11-14
Estimated Expiration
2041-03-31

AI Technical Summary

Technical Problem

Injection devices often require refrigeration to maintain medication at appropriate storage temperatures, causing discomfort to patients due to the significant temperature difference during administration.

Method used

Incorporation of a thermal bridge within the injection device with a thermal conductivity of 10 W/mk or more to facilitate rapid heating of the medication from storage temperature to a more comfortable injection temperature by conducting heat between the inner and outer surfaces.

Benefits of technology

The thermal bridge efficiently warms the medication to a suitable injection temperature quickly, reducing patient discomfort by minimizing the temperature difference upon use.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007583828000002
    Figure 0007583828000002
  • Figure 0007583828000003
    Figure 0007583828000003
  • Figure 0007583828000004
    Figure 0007583828000004
Patent Text Reader

Abstract

A drug delivery device comprising: an outer surface; an area for receiving a drug container, the area having at least one inner surface for contacting and supporting the received drug container; and a thermal bridge extending between the at least one inner surface and the outer surface and conducting heat between the inner surface and the outer surface, the thermal bridge having a thermal conductivity of 10 W / mk or greater.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to an injection device for medication. [Background technology]

[0002] Injection devices, such as auto-injectors, typically have a sealed container of medication and a needle for injecting the medication into a patient. During injection, a drive mechanism displaces a plunger into the medication container to dispense the medication through the needle.

[0003] In many cases, injection devices must be stored in a refrigerator to maintain the medication at the proper storage temperature, which is significantly lower than body temperature, which can cause discomfort to the patient during injection. Summary of the Invention [Means for solving the problem]

[0004] According to the present invention there is provided a drug delivery device including an injection device comprising: an outer surface; an area for receiving a drug container, the area having at least one inner surface for contacting and supporting the received drug container; and a thermal bridge extending between the at least one inner surface and the outer surface and conducting heat between the inner surface and the outer surface, the thermal bridge having a thermal conductivity of 10 W / mk or greater.

[0005] Thus, the device is configured to warm the medication to a more suitable injection temperature more quickly after removal from the refrigerator.

[0006] The inner and outer surfaces are integrally formed with a thermal bridge to provide an uninterrupted conductive path between the inner and outer surfaces.

[0007] Thus, heat transfer between the inner and outer surfaces is maximized.

[0008] The outer surface may be an outer surface of a housing.

[0009] Thus, the medication is heated more efficiently when the device is handled, with the outer surface conducting heat away from the user's hand.

[0010] The thermal bridge is integrally formed as part of the housing, thus making the device simply constructed.

[0011] The thermal bridge may include a region of the housing having an increased wall thickness, the inner diameter of said region of increased wall thickness being substantially the same as the outer diameter of the drug container that is received therein.

[0012] The thermal bridge therefore extends around the entire circumference of the drug container to maximise the contact area for heat transfer between the drug container and the thermal bridge.

[0013] The housing may include first and second members, the thermal bridge being integrally formed with the first member.

[0014] Therefore, only the first member of the housing needs to comprise a material having a thermal conductivity greater than 10 W / mk, thereby reducing the manufacturing costs of the device.

[0015] The thermal bridge may include a collar disposed between the first and second members of the housing, the collar including a cylindrical section having an inner diameter substantially the same as an outer diameter of the drug container to be received therein.

[0016] Thus, only the collar need comprise a material having a thermal conductivity greater than 10 W / mk, thereby reducing the manufacturing costs of the device. Additionally, the first and second members of the housing can be made from conventional plastic materials that are not as cold to the touch as more thermally conductive materials, making device 10 more comfortable to handle when removed from the refrigerator.

[0017] The thermal bridge may include a material having a thermal conductivity greater than 70 W / mK.

[0018] Thus, heat is transferred much more quickly between the inner and outer surfaces.

[0019] The thermal bridge may extend in contact with 20% of the exterior surface of the drug container.

[0020] Thus, a large contact area is provided between the drug container and the thermal bridge for efficient heat transfer.

[0021] The thermal bridge may hold the drug container in a fixed position relative to the housing by an interference fit.

[0022] A thermal bridge may hold the drug container in a fixed position relative to the housing, the thermal bridge being bonded to the drug container by an adhesive having a thermal conductivity greater than 2 W / mK.

[0023] The drug container may include a material having a thermal conductivity of greater than 10 W / mK.

[0024] The thermal bridge may include a thermochromic material configured to change color depending on the temperature of the thermal bridge.

[0025] Therefore, the user can check whether the device is warmed up.

[0026] The exterior surface of the device may include colored regions that correspond to the color of the thermochromic material when the thermal bridge reaches a predetermined temperature.

[0027] Thus, the user can ascertain whether the device has warmed up sufficiently to bring the medication to a comfortable injection temperature.

[0028] The present invention also provides a system comprising a heater and a device as described in any one of claims 1 to 13, wherein the heater comprises a U-shaped channel for receiving the device, and a heating surface of the U-shaped channel contacts an outer surface of the device when the device is received.

[0029] Also according to the present invention there is provided a method of operating a drug delivery device, the drug delivery device comprising: With the exterior; Medication containers and; a thermal bridge extending between the medicament container and the exterior surface, the thermal bridge having a thermal conductivity of 10 W / mk or greater; wherein the method comprises: A method is provided that includes contacting an exterior surface of the medication delivery device with a heat source to heat a medication within a medication container from a storage temperature to an injection temperature.

[0030] The heater allows the device to be brought up to a comfortable injection temperature more quickly.

[0031] Embodiments of the present invention will now be described, by way of example only, with reference to the accompanying drawings, in which: [Brief description of the drawings]

[0032] [Figure 1A] 1 is a schematic side view of an injection device and removable cap embodying the present invention; [Figure 1B] FIG. 1B is a schematic side view of the injection device of FIG. 1A with the cap removed from the housing. [Diagram 2] FIG. 1 is a cross-sectional view of one embodiment of the present invention. [Diagram 3] FIG. 2 is a cross-sectional view of another embodiment of the present invention. [Figure 4] FIG. 2 is a cross-sectional view of another embodiment of the present invention. [Diagram 5] FIG. 2 is a cross-sectional view of another embodiment of the present invention. [Figure 6] FIG. 1 illustrates a system according to the present invention. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0033] The drug delivery devices described herein are configured to inject a medication into a patient. For example, delivery may be subcutaneous, intramuscular, or intravenous. Such devices may be operated by the patient or a caregiver such as a nurse or doctor, and may include various types of safety syringes, pen injectors, or auto-injectors. The devices may include cartridge-based systems that require a sealed ampoule to be pierced prior to use. The volume of medication delivered by these various devices may range from about 0.5 ml to about 3 ml. Another device may include a pre-filled syringe within the housing of the device. The syringe may be fixed within the housing or movable within the housing, for example from a retracted position to an operative extended position.

[0034] In combination with a particular drug, the devices described herein can also be customized to operate within required specifications. For example, the device can be customized to inject the drug within a particular period of time (e.g., about 3 to about 20 seconds for an auto-injector). Other specifications may include low or minimal levels of discomfort, or specific conditions related to human factors, longevity, expiration date, biocompatibility, environmental considerations, etc. Such variations may result from a variety of factors, such as, for example, drugs with viscosities ranging from about 3 cP to about 50 cP. Thus, drug delivery devices often include hollow needles ranging in size from about 25 to about 31 gauge. Common sizes are 17 and 29 gauge.

[0035] The delivery devices described herein may also include one or more automated features. For example, one or more of needle and cartridge combination, needle insertion, drug injection, and needle retraction may be automated. Energy for one or more automated steps may be provided by one or more energy sources. The energy sources may include, for example, mechanical, pneumatic, chemical, or electrical energy. For example, a mechanical energy source may include a spring, lever, elastomer, or other mechanical mechanism to store or release energy. One or more energy sources may be combined into a single device. The device may further include gears, valves, or other mechanisms to convert energy into movement of one or more components of the device.

[0036] The one or more automated features of the auto-injector can each be activated by an activation mechanism. Such an activation mechanism can include one or more of an actuator, e.g., a button, a lever, a needle sleeve, or other activation components. Activation of an automated feature can be a one-step or multi-step process. That is, a user may need to activate one or more activation components to trigger an automated feature. For example, in a one-step process, a user may depress a needle sleeve against his or her body to trigger an injection of a medication. Other devices may require multi-step activation of an automated feature. For example, a user may need to depress a button to retract a needle shield to trigger an injection.

[0037] Additionally, activation of one automated function may activate one or more subsequent automated functions, thereby forming an activation sequence. For example, activation of a first automated function may activate at least two of needle and cartridge pairing, needle insertion, drug injection, and needle retraction. Some devices may require a specific sequence of steps to cause one or more automated functions to occur. Other devices may operate with a sequence of independent steps.

[0038] Some delivery devices may include one or more features of a safety syringe, a pen injector, or an auto-injector. For example, a delivery device may include a mechanical energy source configured to automatically inject a medication (typically found in an auto-injector) and a dose setting mechanism (typically found in a pen injector).

[0039] According to some embodiments of the present disclosure, an exemplary drug delivery device 10 is shown in Figures 1A and 1B. The device 10 is configured to inject a drug into a patient's body, as described above. The device 10 includes a housing 11 that includes a drug container 18 that defines a reservoir containing the drug to be injected, and components required to facilitate one or more steps of the delivery process. The drug container 18 can be a cartridge or a pre-filled syringe.

[0040] Device 10 may also include a cap 12 that may be removably attached to housing 11. Typically, a user must remove cap 12 from housing 11 before device 10 can be operated.

[0041] As shown, the housing 11 is substantially cylindrical and has a substantially constant diameter along a longitudinal axis AA. The housing 11 has a distal region D and a proximal region P. The term "distal" refers to a position relatively closer to the injection site and the term "proximal" refers to a position relatively farther from the injection site.

[0042] The device 10 may also include a needle sleeve 19 coupled to the housing 11 to permit movement of the needle sleeve 19 relative to the housing 11. For example, the sleeve 19 may move in a longitudinal direction parallel to the longitudinal axis AA. Specifically, movement of the sleeve 19 in a proximal direction may permit the needle 17 to extend from a distal region D of the housing 11.

[0043] Insertion of needle 17 can be accomplished by a number of mechanisms. For example, needle 17 is fixedly positioned relative to housing 11 and is initially located within an extended needle sleeve 19. The distal end of sleeve 19 is placed on the patient's body, and proximal movement of sleeve 19 by moving housing 11 distally exposes the distal end of needle 17. Such relative movement allows the distal end of needle 17 to extend into the patient's body. Such insertion is referred to as a "manual" insertion, since needle 17 is manually inserted by the patient manually moving housing 11 relative to sleeve 19.

[0044] Another form of insertion is "automated," in which needle 17 moves relative to housing 11. Such insertion can be triggered by movement of sleeve 19 or by another form of actuation, such as, for example, button 13. As shown in FIGS. 1A and 1B, button 13 is located at the proximal end of housing 11. However, in other embodiments, button 13 can be located on the side of housing 11.

[0045] Other manual or automated configurations can include drug injection or needle retraction, or both. Injection is a process in which the bung or piston 14 is moved from a proximal position in the reservoir of the cartridge 18 to a more distal position to force the medicament out of the cartridge 18 and through the needle 17. In some embodiments, a drive mechanism 20 (shown in FIGS. 2-5) is activated to force the medicament out of the cartridge 18. The drive mechanism 20 includes a drive spring 21. The drive spring 21 is under compression before the drive mechanism 20 is activated. A proximal end of the drive spring 21 can be secured within the proximal region P of the housing 11, and a distal end of the drive spring 21 can be configured to apply a compressive force to a proximal face of the piston 14. After activation, at least a portion of the energy stored in the drive spring 21 can be applied to the proximal face of the piston 14. This compressive force can act on the piston 14 to move it in a distal direction. Such distal movement acts to compress the liquid medicament within cartridge 18 , forcing the liquid medicament out of needle 17 .

[0046] After injection, needle 17 can be retracted into sleeve 19 or housing 11. Retraction can occur when sleeve 19 moves distally as the user removes device 10 from the patient's body. This can occur when needle 17 remains in a fixed position relative to housing 11. Sleeve 19 can be locked after the distal end of sleeve 19 moves past the distal end of needle 17 and needle 17 is covered. Such locking can include locking proximal movement of sleeve 19 relative to housing 11.

[0047] Another form of needle retraction may occur when the needle 17 is moved relative to the housing 11. Such movement may occur when the cartridge 18 within the housing 11 is moved proximally relative to the housing 11. This proximal movement may be achieved by using a retraction spring (not shown) located in the distal region D. The compressed retraction spring, when activated, may provide sufficient force to the cartridge 18 to move it proximally. After sufficient retraction, the relative movement of the needle 17 and the housing 11 may be locked by a locking mechanism. Additionally, the button 13 or other components of the device 10 may be locked as desired.

[0048] FIG. 2 shows an injection device 10 according to one embodiment of the invention, with similar features being given the same reference numbers.

[0049] The device 10 includes a thermal bridge 22 configured to conduct heat between the drug cartridge 18 and an exterior surface 24 of the device 10. Thus, heat applied to the exterior surface 24 of the device 10 is conducted to the drug cartridge 18, heating the drug held therein.

[0050] When in use, the device 10 is stored in a refrigerator to keep the medication at a storage temperature, which is significantly lower than body temperature, and which varies but is typically between -4 and 4°C.

[0051] It is known that a patient's pain during an injection corresponds to the temperature of the drug being injected. Drugs injected at storage temperature may cause increased pain compared to drugs injected at higher temperatures. Ideally, the drug is at approximately body temperature during injection to minimize pain.

[0052] Thus, by providing a thermal bridge 22 between the exterior surface 24 of the device 10 and the medication cartridge 18, it is possible to heat the medication more quickly by applying heat to the exterior surface 24. When the ambient temperature is higher than the storage temperature, heat is applied passively by simply removing the device 10 from the refrigerator. Alternatively, heat is applied by the user's hand as the user grasps the device 10. It is also envisioned that a dock 40 may be provided to actively heat the device, as described further below with reference to FIG. 6.

[0053] In the embodiment illustrated by Figure 2, the thermal bridge 22 is integrally formed with the housing 11, upstands from an inner surface 25 of the housing 11 and contacts an outer surface 26 of the drug cartridge 18. Figure 2 shows a cross section taken through the device 10. Because the thermal bridge 22 is integrally formed with the housing 11, the thermal bridge 22 provides an uninterrupted conductive path between the outer surface 26 of the drug cartridge 18 and the outer surface 24 of the housing 11.

[0054] In the illustrated embodiment, the thermal bridge 22 comprises a region of the housing 11 having an increased wall thickness, the inner diameter of said region being reduced compared to the remainder of the housing 11. This inner diameter is substantially the same as the outer diameter of the medicament cartridge 18, such that the inner surface 25 of said region closely abuts the outer surface 26 of the medicament cartridge 18. The thermal bridge 22 therefore extends around the entire circumference of the cartridge 18 ensuring a large contact area between the thermal bridge 22 and the cartridge 18. This provides as large an area as possible for heat transfer, the importance of which will be readily understood by those skilled in the art from Fourier's Law.

[0055] Advantageously, thermal bridge 22 provides a shoulder 27 for supporting the proximal end of sleeve retraction spring 28. Shoulder 27 is provided where the inner diameter of housing 11 narrows in a step to form thermal bridge 22. Sleeve retraction spring 28 biases sleeve 19 away from the distal end of housing 11 to hide needle 17.

[0056] The cap 12 sits over the sleeve 19. A needle shield 29 is also provided to surround the needle 17 for added safety. The needle shield 29 is grasped by a wall 30 extending from the cap 12 so that the needle shield 29 is removed at the same time as the cap 12.

[0057] To maximize heat transfer between the exterior surface 24 of the housing 11 and the exterior surface 26 of the cartridge 18, the thermal bridge 22 is preferably made from a material with a relatively high thermal conductivity, by relatively high, in comparison to the typical types of plastics used to form housings for injection devices. In the embodiments described herein, the thermal bridge 22 has a thermal conductivity of greater than 10 W / mK.

[0058] In another embodiment shown in Figure 3 (where similar features are given the same reference numbers), the housing 11 is divided into first and second members 11a and 11b. The first member 11a forms the distal region D of the device 10 and houses the drug cartridge 18, and the second member 11b forms the proximal region P of the device 10 and houses the drive mechanism 20.

[0059] In this embodiment, the thermal bridge 22 is integrally formed with the first member 11a of the housing 11, upstands from an inner surface 25a of the first member 11a of the housing 11 and contacts an outer surface 26 of the drug cartridge 18. Figure 3 shows a cross section taken through the device 11. As with the embodiment of Figure 2, because the thermal bridge 22 is integrally formed with the housing 11, the thermal bridge 22 provides an uninterrupted conductive path between the outer surface 26 of the drug cartridge 18 and the outer surface 24 of the housing 11.

[0060] The thermal bridge 22 comprises a region of the first member 11a of the housing 11 having an increased wall thickness, the inner diameter of said region being reduced compared to the remainder of the housing 11. As with the embodiment of Figure 2, this inner diameter is substantially the same as the outer diameter of the drug cartridge 18, such that the inner surface 25a of said region closely abuts the outer surface 26 of the drug cartridge 18.

[0061] The first member 11a of the housing 11 is attached to the second member 11b of the housing 11 by a threaded connection 31. In the illustrated embodiment, the first member 11a of the housing 11 includes an externally threaded end 31a that cooperates with an internally threaded end 31b of the second member 11b of the housing 11 to attach the first and second members 11a, 11b of the housing 11.

[0062] An advantage of splitting the first and second parts 11a, 11b of the housing 11 is that the first part 11a of the housing 11, and therefore the thermal bridge 22, can be made from a different, more thermally conductive material than the second part 11b of the housing 11, for example a material having a thermal conductivity greater than 10 W / mK, thus reducing the cost of the device 10, where a more thermally conductive material has a higher unit cost.

[0063] In another embodiment of the invention shown in FIG. 4 (similar features are given the same reference numbers), the housing 11 includes first and second members 11c, 11d and a collar 32 separating the first and second members 11c, 11d. The first member 11c of the housing 11 forms the distal end D of the device 10, and the second member 11d of the housing 11 forms the proximal end P of the device 10. In the embodiment of FIG. 4, the first and second members 11c, 11d are not directly attached, but are attached to opposite ends of the collar 32 by threaded connections 33, respectively. The collar 32 is disposed over the cartridge 18. The collar 32 includes a cylindrical section having an inner diameter substantially the same as the outer diameter of the drug cartridge 18, such that the inner surface of the collar 32 closely abuts the outer surface of the drug cartridge 18. The outer surface 34 of the collar 32 is collinear with the outer surfaces of the first and second members 11c, 11d of the housing 11 and forms part of the outer surface 24 of the device 10. The collar 32 thus provides an uninterrupted conductive path between the thermal bridge 22 and the outer surface 26 of the drug cartridge 18 and the outer surface 24 of the device 10.

[0064] In the illustrated embodiment, each end of the collar 32 is provided with an internal thread 33a to cooperate with a corresponding externally threaded end 33b of the first and second members 11c, 11d of the housing 11. An advantage of this embodiment is that the collar 32, and thus the thermal bridge 22, can be made from a different, more thermally conductive material than the first and second members 11c, 11d of the housing 11, for example a material having a thermal conductivity greater than 10 W / mK. Thus, the cost of the device 11 is reduced, in cases where a more thermally conductive material has a higher unit cost. Another advantage is that the first and second members 11c, 11d of the housing 11 can be made from a conventional plastic material that is not as cold to the touch as a more thermally conductive material, making the device 10 more comfortable to handle when removed from the refrigerator.

[0065] In another embodiment of the invention shown in FIG. 5 (where similar features are given the same reference numbers), the thermal bridge 22 includes an insert 50 disposed between the housing 11 and the drug cartridge 18. An inner surface 51 of the insert 50 is located on the outer surface 26 of the drug cartridge 18, and an outer surface 52 of the insert 50 is located on the inner surface 25 of the housing 11. Thus, the insert 50 provides a conductive path between the drug cartridge 18 and the housing 11. Preferably, the insert 50 is cylindrical, such that the insert extends around the entire circumference of the cartridge 18 to maximize the surface area in contact with the cartridge 18. However, the insert 50 may be divided into individual bridge portions to save on material costs.

[0066] The insert 50 may hold the cartridge 18 in a fixed relationship to the housing 11 by an interference fit between the inner and outer surfaces 51, 52 of the insert 50 and the corresponding surfaces 26, 25 of the cartridge 18 and the housing 11, respectively. Alternatively, a thermally conductive adhesive may be used to bond the inner and outer surfaces 51, 52 of the insert 50 to the corresponding surfaces 26, 25 of the cartridge 18 and the housing 11, respectively.

[0067] In the embodiment described above, the thermal bridge 22 extends around the entire circumference of the cartridge 18 to ensure a large contact area between the thermal bridge 22 and the cartridge 18. As discussed above, this provides the largest possible area for heat transfer. Preferably, the thermal bridge 22 extends along the length of the cartridge 18 so as to contact at least 50% of the drug-containing portion 23 of the cartridge 18.

[0068] Also preferably, the thermal bridge 22 is configured to hold the drug cartridge 18 in a fixed relationship relative to the housing 11. The thermal bridge 22 may hold the drug container 18 by friction. For example, the drug cartridge 18 is held in the thermal bridge 22 by an interference fit. Alternatively, an adhesive may be used between the thermal bridge 22 and the outer surface 26 of the drug cartridge 18. An adhesive may be selected that has a relatively high thermal conductivity, such as a thermal conductivity of greater than 2 W / mK.

[0069] Since the objective of the present invention is to increase the rate at which the drug is brought up to a suitable temperature, the drug cartridge 18 itself is also made from a relatively highly conductive material, as compared to conventional materials for constructing cartridges, such as glass or common types of polymers. For example, the cartridge 18 is made from stainless steel.

[0070] Also, in embodiments of the present invention, regions of the exterior surface 24 of the device 10 may be configured to change color in response to a change in temperature. For example, the exterior surface 24 of the device 10 may be provided with a strip of thermochromic material 35 (as shown in FIG. 6). Thus, as the device 10 warms up, the color of the exterior surface 24 changes to indicate this temperature change to the user. Preferably, the exterior surface 24 of the device 10 includes a colored reference strip 36 that corresponds to the color of the thermochromic material when the thermal bridge 22 reaches a predetermined temperature, the predetermined temperature being a temperature at which the medication can be more comfortably injected into the patient. The user may compare the color of the thermochromic portion of the exterior surface 24 to the colored region to determine that the device is ready for use. Suitable thermochromic materials may include liquid crystal materials or leuco dyes.

[0071] It should be appreciated that an increase in the temperature of the agent causes a corresponding decrease in the viscosity of the agent. Advantageously, for a given force applied to the piston 14, the decrease in the viscosity of the agent results in a corresponding increase in the rate at which the agent is expelled from the device 10.

[0072] Patients may prefer that injections be administered quickly, and therefore the present invention allows the medication to be heated more quickly from its storage temperature so that the patient or user of device 10 can inject the medication at a preferred rate.

[0073] In one embodiment, the colored reference strip 36 represents a color scale, with uniquely colored increments of the scale corresponding to the colors of the thermochromic strip 35 at different injection speeds. Each injection speed is labeled adjacent to the corresponding increment. Alternatively, the colored reference strip 36 may be a continuous scale, fading from one color representing a slower injection speed to another color representing a faster injection speed. The continuous scale is labeled with a corresponding label, such as "fast" or "slow."

[0074] The present invention also provides a system including a dock 40 for heating the injection device 10 described above. The dock 40 (hereinafter simply referred to as "heater 40") is shown in FIG. 6. The heater 40 is an independent component of a system configured to heat the injection device 10 after it is removed from a refrigerator. The heater 40 includes a base 41 for standing the heater on a horizontal surface and a housing 42 that encloses the internal components of the heater 40. The housing 42 is provided with a U-shaped channel 43 or docking surface for receiving the device 10. The U-shaped channel 43 extends parallel to the base 41, so that the injection device 10 is stably supported when received. The heater 40 includes a heater element (not shown) for heating the U-shaped channel 43. The heater element is internal to the housing 42. Any suitable electronic heating element can be used. The heater element is automatically activated by a pressure switch when the device 10 is received in the U-shaped channel 43. Alternatively, the heater 40 may include a switch 44 in the housing 42 for a user to manually activate the heater 40 after placing the injection device 10 in the U-shaped channel 43. It should be appreciated that in other embodiments, the docking surface need not be U-shaped, but may be any shape that allows for effective heat transfer between the heater 40 and the injection device 10. For example, the docking surface may be annular to surround the injection device 10 when it is received.

[0075] The following table shows exemplary materials that can be used to form the thermal bridge and their thermal conductivities. All thermal conductivities are listed for the corresponding material at room temperature.

[0076] [Table 1]

[0077] The embodiments of the injection devices described herein are configured to accept either a drug cartridge or a drug pre-filled syringe, and as used herein, the term "drug container" is intended to encompass both drug cartridges and pre-filled syringes.

[0078] The term "drug" or "medicament" is used herein to describe one or more pharmacologic active compounds. As described below, a drug or medicament may include at least one small molecule or macromolecule or combinations thereof in various types of formulations for the treatment of one or more diseases. Exemplary pharmacologic active compounds may include small molecules, polypeptides, peptides, and proteins (e.g., hormones, growth factors, antibodies, antibody fragments, and enzymes), carbohydrates and polysaccharides, as well as nucleic acids, double-stranded or single-stranded DNA (including naked and cDNA), RNA, antisense nucleic acids such as antisense DNA and RNA, small interfering RNA (siRNA), ribozymes, genes, and oligonucleotides. Nucleic acids can be incorporated into vectors, plasmids, or molecular delivery systems such as liposomes. Mixtures of one or more of these drugs are also contemplated.

[0079] The term "drug delivery device" is intended to encompass any type of device or system configured to administer a drug to a human or animal body. Without limitation, the drug delivery device may be an injector device (e.g., a syringe, pen injector, autoinjector, large volume device, pump, perfusion system, or other device configured for intraocular, subcutaneous, intramuscular, or intravascular delivery), a skin patch (e.g., osmotic, chemical, microneedle), an inhaler (e.g., nasal or pulmonary), an implant (e.g., coated stent, capsule), or a delivery system for the gastrointestinal tract. The drugs described herein may be particularly useful in an injector device that includes a needle, e.g., a small gauge needle.

[0080] The drug or agent can be contained in a primary package or "drug container" adapted for use in a drug delivery device. The drug container can be, for example, a cartridge, syringe, reservoir, or other vessel configured to provide a chamber suitable for storage (e.g., short-term or long-term storage) of one or more pharma- ceutically active compounds. For example, in some cases, the chamber can be designed to store the drug for at least one day (e.g., from one day to at least 30 days). In some cases, the chamber can be designed to store the drug for about one month to about two years. Storage can be at room temperature (e.g., about 20° C.) or at refrigerated temperatures (e.g., from about −4° C. to about 4° C.). In some cases, the drug container can be or include a dual-chamber cartridge configured to separately store two or more components of a drug formulation (e.g., a drug and a diluent, or two different types of drugs), one in each chamber. In such cases, the two chambers of the dual-chamber cartridge can be configured to allow mixing between two or more components of a drug or agent prior to and / or during administration to the human or animal body. For example, the two chambers can be configured to be in fluid communication with each other (e.g., via a conduit between the two chambers) and to allow mixing of the two components by a user, if desired, prior to administration. Alternatively or additionally, the two chambers can be configured to allow mixing upon administration of the components to the human or animal body.

[0081] The drug delivery devices and drugs according to the present invention can be used for the treatment and / or prevention of many different types of disorders. Exemplary disorders include, for example, diabetes or complications associated with diabetes, such as diabetic retinopathy, thromboembolic disorders, such as deep vein thromboembolism or pulmonary thromboembolism. Further exemplary disorders are acute coronary syndrome (ACS), angina, myocardial infarction, cancer, macular degeneration, inflammation, hay fever, atherosclerosis and / or rheumatoid arthritis.

[0082] Exemplary drugs for the treatment and / or prevention of diabetes or complications associated with diabetes include insulin, e.g., human insulin, or a human insulin analog or derivative, glucagon-like peptide (GLP-1), a GLP-1 analog or GLP-1 receptor agonist, or an analog or derivative thereof, a dipeptidyl peptidase-4 (DPP4) inhibitor, or a pharma- ceutically acceptable salt or solvate thereof, or any mixture thereof. As used herein, the term "derivative" refers to any substance that is sufficiently structurally similar to the original substance so as to have substantially the same functionality or activity (e.g., therapeutic effect).

[0083] Exemplary insulin analogs are Gly(A21), Arg(B31), Arg(B32) human insulin (insulin glargine); Lys(B3), Glu(B29) human insulin; Lys(B28), Pro(B29) human insulin; Asp(B28) human insulin; human insulin in which the proline at position B28 is replaced by Asp, Lys, Leu, Val or Ala and Lys at position B29 may be replaced by Pro; Ala(B26) human insulin; Des(B28-B30) human insulin; Des(B27) human insulin and Des(B30) human insulin.

[0084] Exemplary insulin derivatives include, for example, B29-N-myristoyl-des(B30) human insulin; B29-N-palmitoyl-des(B30) human insulin; B29-N-myristoyl human insulin; B29-N-palmitoyl human insulin; B28-N-myristoyl-LysB28ProB29 human insulin; B28-N-palmitoyl-LysB28ProB29 human insulin; B30-N-myristoyl-ThrB29Lys B30 human insulin; B30-N-palmitoyl-ThrB29LysB30 human insulin; B29-N-(N-palmitoyl-gamma-glutamyl)-des(B30) human insulin; B29-N-(N-lithocholyl-gamma-glutamyl)-des(B30) human insulin; B29-N-(ω-carboxyheptadecanoyl)-des(B30) human insulin and B29-N-(ω-carboxyheptadecanoyl) human insulin. Exemplary GLP-1, GLP-1 analogs and GLP-1 receptor agonists include, for example, lixisenatide / AVE0010 / ZP10 / Lyxumia, exenatide / exendin-4 / Byetta / Bydureon / ITCA650 / AC-2993 (a 39 amino acid peptide produced by the salivary glands of the flathead monster), liraglutide / Victoza, semaglutide, taspoglutide, synclear / albiglutide, dulaglutide, rExendin-4, CJC-1134-PC, PB-1023, TTP-054, Langrena These include: cefotide / HM-11260C, CM-3, GLP-1 Erigen, ORMD-0901, NN-9924, NN-9926, NN-9927, nodexene, Viadol-GLP-1, CVX-096, ZYOG-1, ZYD-1, GSK-2374697, DA-3091, MAR-701, MAR709, ZP-2929, ZP-3022, TT-401, BHM-034, MOD-6030, CAM-2036, DA-15864, ARI-2651, ARI-2255, exenatide-XTEN and glucagon-Xten.

[0085] An exemplary oligonucleotide is, for example, the cholesterol-lowering antisense therapeutic mipomersen / quinamro for the treatment of familial hypercholesterolemia.

[0086] Exemplary DPP4 inhibitors are vidagliptin, sitagliptin, denagliptin, saxagliptin, berberine.

[0087] Exemplary hormones include pituitary or hypothalamic hormones or regulatory active peptides and their antagonists, such as gonadotropins (follitropin, lutropin, chorion gonadotropin, menotropin), somatropine (somatropin), desmopressin, terlipressin, gonadorelin, triptorelin, leuprorelin, buserelin, nafarelin, and goserelin.

[0088] Exemplary polysaccharides include glycosaminoglycans, hyaluronic acid, heparin, low molecular weight heparin or very low molecular weight heparin or derivatives thereof, or sulfated polysaccharides, such as the above-mentioned polysaccharides in polysulfated form, and / or their pharmaceutically acceptable salts.An example of a pharmaceutically acceptable salt of polysulfated low molecular weight heparin is enoxaparin sodium.An example of a hyaluronic acid derivative is Hylan G-F20 / Synvisc, sodium hyaluronate.

[0089] The term "antibody" as used herein refers to an immunoglobulin molecule or an antigen-binding portion thereof. Examples of antigen-binding portions of an immunoglobulin molecule include F(ab) and F(ab')2 fragments that retain the ability to bind to an antigen. The antibody can be a polyclonal antibody, a monoclonal antibody, a recombinant antibody, a chimeric antibody, a deimmunized or humanized antibody, a fully human antibody, a non-human (e.g., murine) antibody, or a single chain antibody. In some embodiments, the antibody has effector function and is capable of fixing complement. In some embodiments, the antibody has reduced or no binding ability to Fc receptors. For example, the antibody can be an isotype or subtype, an antibody fragment, or a mutant that does not support binding to Fc receptors, e.g., has a mutation or deletion of the Fc receptor binding region.

[0090] The term "fragment" or "antibody fragment" refers to a polypeptide (e.g., antibody heavy and / or light chain polypeptide) derived from an antibody polypeptide molecule that does not include the full-length antibody polypeptide but comprises at least a portion of the full-length antibody polypeptide that is still capable of binding to an antigen. An antibody fragment may include truncated portions of a full-length antibody polypeptide, but the term is not limited to such truncated fragments. Antibody fragments useful in the present invention include, for example, Fab fragments, F(ab')2 fragments, scFv (single-chain Fv) fragments, linear antibodies, monospecific or multispecific antibody fragments, such as bispecific, trispecific, and multispecific antibodies (e.g., diabodies, triabodies, tetrabodies), minibodies, chelating recombinant antibodies, tribodies or bibodies, intrabodies, nanobodies, small modular immunopharmaceuticals (SMIPs), binding domain immunoglobulin fusion proteins, camelized antibodies, and VHH-containing antibodies. Additional examples of antigen-binding antibody fragments are known in the art.

[0091] The term "complementarity determining region" or "CDR" refers to short polypeptide sequences in the variable regions of both heavy and light chain polypeptides that are primarily responsible for mediating specific antigen recognition. The term "framework region" refers to amino acid sequences in the variable regions of both heavy and light chain polypeptides that are not CDR sequences and are primarily responsible for maintaining the proper arrangement of CDR sequences to allow antigen binding. Although framework regions themselves typically do not directly participate in antigen binding, as is known in the art, certain residues in the framework regions of a particular antibody may be directly involved in antigen binding or may affect the ability of one or more amino acids in the CDR to interact with an antigen.

[0092] Exemplary antibodies are anti-PCSK-9 mAbs (e.g., alirocumab), anti-IL-6 mAbs (e.g., sarilumab), and anti-IL-4 mAbs (e.g., dupilumab).

[0093] The compounds described herein can be used in pharmaceutical preparations that include (a) the compounds or their pharmaceutically acceptable salts, and (b) pharmaceutically acceptable carriers.The compounds can also be used in pharmaceutical preparations that include one or more other active pharmaceutical ingredients, or in pharmaceutical preparations in which the compounds or their pharmaceutically acceptable salts are the only active ingredient.Thus, the pharmaceutical preparations of the present disclosure encompass any preparation made by mixing the compounds described herein with a pharmaceutically acceptable carrier.

[0094] Pharmaceutically acceptable salts of any of the drugs described herein are contemplated for use in the drug delivery device. Pharmaceutically acceptable salts are, for example, acid addition salts and base salts. Acid addition salts are, for example, HCl or HBr salts. Base salts are, for example, salts with a cation selected from an alkali or alkaline earth metal, for example, Na+, or K+, or Ca2+, or an ammonium ion N+(R1)(R2)(R3)(R4), where R1 to R4 are each independently: hydrogen, an optionally substituted C1-C6-alkyl group, an optionally substituted C2-C6-alkenyl group, an optionally substituted C6-C10-aryl group, or an optionally substituted C6-C10-heteroaryl group. Further examples of pharma-ceutically acceptable salts are known to those skilled in the art.

[0095] Pharmaceutically acceptable solvates are, for example, hydrates or alkanolates, such as methanolates or ethanolates.

[0096] Those skilled in the art will understand that modifications (addition and / or removal) of the various components of the materials, formulations, devices, methods, systems, and embodiments described herein may be made without departing from the full scope and spirit of the invention, and the invention encompasses all such modifications and all equivalents thereof.

Claims

1. 1. A drug delivery device comprising: The exterior and; an area for receiving a medication container, the area having at least one inner surface for contacting and supporting the received medication container; a thermal bridge extending between at least one of the inner surface and the outer surface and conducting heat between the inner surface and the outer surface, the thermal bridge having a thermal conductivity of 10 W / mK or more; The drug delivery device comprising:

2. 10. The drug delivery device of claim 1, wherein the inner and outer surfaces are integrally formed with a thermal bridge to provide an uninterrupted conductive path between the inner and outer surfaces.

3. The drug delivery device of claim 2 , wherein the outer surface is an outer surface of a housing.

4. The thermal bridge is integrally formed as part of the housing; the thermal bridge includes a region of the housing having an increased wall thickness, the inner diameter of said region of increased wall thickness being substantially the same as the outer diameter of the drug container to be received therein; The drug delivery device of claim 3.

5. The drug delivery device of claim 3 , wherein the housing includes first and second members, the thermal bridge being integrally formed in the first member.

6. 3. The drug delivery device of claim 1 or 2, wherein the thermal bridge includes a collar disposed between the first and second members of the housing, the collar including a cylindrical section having an inner diameter substantially the same as an outer diameter of the drug container to be received therein.

7. A drug delivery device according to any preceding claim, wherein the thermal bridge comprises a material having a thermal conductivity greater than 70 W / mK.

8. The thermal bridge holds the drug reservoir in a fixed position relative to the housing by an interference fit. The drug delivery device of any one of claims 1 to 7, configured to hold a vessel.

9. The drug delivery device of any one of claims 1 to 8, further comprising a drug reservoir.

10. 10. The drug delivery device of claim 9, wherein the thermal bridge holds the drug container in a fixed position relative to the housing, the thermal bridge being bonded to the drug container by an adhesive having a thermal conductivity greater than 2 W / mK.

11. 11. The drug delivery device of claim 9 or 10, wherein the drug container comprises a material having a thermal conductivity greater than 10 W / mK.

12. A drug delivery device according to any preceding claim, comprising a thermochromic material configured to change colour depending on the temperature of the thermal bridge.

13. 13. The drug delivery device of claim 12, wherein the exterior surface of the device includes colored areas that correspond to the color of the thermochromic material when the thermal bridge reaches the injection temperature.

14. 14. A system comprising a heater and a device according to any one of claims 1 to 13, the heater comprising a heated docking surface configured to contact an outer surface of the device when the device is placed on the heated docking surface.

15. 1. A method of operating a drug delivery device, comprising: The exterior and; A drug container; a thermal bridge extending between the medicament container and the exterior surface, the thermal bridge having a thermal conductivity of 10 W / mK or greater; wherein the method comprises: contacting an exterior surface of the medication delivery device with the heat source, the heat source then heating the medication in the medication container from a storage temperature to an injection temperature; The method.

Citation Information

Patent Citations

  • Syringe set and heating device for same

    US20100305504A1

  • Devices, systems and methods for controlling environmental conditions of substances

    US20180333330A1